PARP inhibition is moving on from breast and ovarian cancer to the treatment of patients with prostate cancer and BRCA1/2 mutation. Olaparib (Lynparza) reduced the risk for death by 31% versus enzalutamide (Xtandi) or abiraterone (Zytiga) in men with metastatic castration-resistant prostate cancer (CRPC) and BRCA1 or BRCA2, and to a lesser extent ATM mutations, according to the final analysis of the phase 3 PROfound trial.
“Practice-Changing” Results Seen with Adjuvant Abemaciclib plus Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer
Adding the oral cyclin-dependent kinase (CDK)4/CDK6 inhibitor abemaciclib (Verzenio) to endocrine therapy led to a significant reduction in the risk for invasive disease recurrence versus endocrine therapy alone in patients with high-risk hormone receptor (HR)-positive, HER2-negative early-stage breast cancer, according to findings from the phase 3 monarchE clinical trial. The results were presented at the 2020 European Society for Medical Oncology (ESMO) virtual meeting and were featured at the meeting press conference.
Cabozantinib plus Nivolumab Offers New First-Line Treatment Option for Patients with Advanced Renal-Cell Carcinoma
The combination of cabozantinib (Cabometyx), a second-generation tyrosine kinase inhibitor (TKI), plus nivolumab (Opdivo), an immune checkpoint inhibitor, significantly improved overall survival (OS) and doubled the objective response rates (ORR) compared with the current standard, sunitinib (Sutent), in treatment-naïve patients with advanced renal-cell carcinoma (RCC), according to the results of the phase 3 CheckMate-9ER clinical trial.
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Adding abemaciclib to endocrine therapy led to a significant reduction in invasive disease recurrence versus endocrine therapy alone in HR-positive, HER2-negative early-stage breast cancer, according to the results of a new study. “This is a very important trial, and the findings will change practice,” said Giuseppe Curigliano, MD, PhD.
Trabectedin/PLD versus Carboplatin/PLD in Recurrent Ovarian Cancer Progressing within 6-12 Months After Last Platinum Line
For patients with recurrent ovarian cancer progressing within 6 to 12 months after their last platinum line, a combination of trabectedin and pegylated liposomal doxorubicin (PLD) did not demonstrate superiority over a combination of carboplatin and PLD.
XMT-1536 is an antibody-drug conjugate that targets the sodium-phosphate cotransporter NaPi2b, which is commonly expressed in solid tumors such as high-grade serous ovarian cancer. Treatment with XMT-1536 results in an overall response rate of 34% in patients with advanced disease; antitumor activity is positively correlated with a higher NaPi2b expression.
Maintenance Olaparib plus Bevacizumab for Newly Diagnosed High-Grade Ovarian Cancer: Second Progression-Free Survival
Results from the PAOLA/ENGOT-ov25 study indicate that adding olaparib to maintenance bevacizumab after first-line platinum-based chemotherapy for patients with newly diagnosed high-grade ovarian cancer improves second progression-free survival and time to second subsequent therapy or death.
Real-World Data on Platinum Therapy in High-Grade Serous Ovarian Cancer Patients Progressing After PARP Inhibitor Treatment
Atezolizumab in combination with paclitaxel, carboplatin, and bevacizumab as first-line treatment for patients with newly diagnosed stage III or stage IV ovarian cancer did not improve progression-free survival or overall survival but exploratory subgroup analyses are ongoing.
Mirvetuximab Soravtansine in Combination with Carboplatin and Bevacizumab in Recurrent Ovarian Cancer
The final results of the FORWARD II phase 1b study investigating the efficacy, safety, and tolerability of mirvetuximab soravtansine in combination with carboplatin and bevacizumab in patients with recurrent platinum-sensitive ovarian cancer revealed an overall response rate of 83% and reasonable tolerability.
Page 1 of 3
Results 1 - 10 of 24
Results 1 - 10 of 24